Literature DB >> 26315943

Isolated facial diplegia in Guillain-Barré syndrome: Bifacial weakness with paresthesias.

Benjamin R Wakerley1,2, Nobuhiro Yuki3.   

Abstract

Bifacial weakness with paresthesias (BFP) is a subtype of Guillain-Barré syndrome defined by rapidly progressive bilateral facial weakness in the absence of other cranial neuropathies, ataxia, or limb weakness. Many patients also complain of distal limb paresthesias and display diminished or absent deep tendon reflexes. BFP is a localized form of Guillain-Barré syndrome and is thought to be caused exclusively by demyelinating- rather than axonal-type neuropathy. Patients with BFP do not display anti-ganglioside IgG antibodies. Since it is rare, many physicians are unfamiliar with BFP, as bilateral facial weakness is more commonly associated with sarcoidosis, Lyme disease, or meningeal pathology. Many patients diagnosed with bilateral Bell palsy may instead have BFP. In this review, we highlight the clinical features of BFP and outline diagnostic criteria.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bell palsy; Guillain-Barré syndrome; Miller Fisher syndrome; bifacial weakness; facial diplegia; paraesthesia

Mesh:

Year:  2015        PMID: 26315943     DOI: 10.1002/mus.24887

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Facial Diplegia with Paresthesia: An Uncommon Variant of Guillain-Barre Syndrome.

Authors:  Prabhat Kumar; Riyaz Charaniya; Anish Bahl; Anindya Ghosh; Juhi Dixit
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  COVID-19-Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome.

Authors:  K L Hutchins; J H Jansen; A D Comer; R V Scheer; G S Zahn; A E Capps; L M Weaver; N A Koontz
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-25       Impact factor: 3.825

3.  A unique association of bifacial weakness, paresthesia and vestibulocochlear neuritis as post-COVID-19 manifestation in pregnant women: a case report.

Authors:  Jehanne Aasfara; Amal Hajjij; Hatim Bensouda; Hamid Ouhabi; Fouad Benariba
Journal:  Pan Afr Med J       Date:  2021-01-13

4.  [Isolated facial diplegia as an atypical variant of Guillain-Barre syndrome after suspected SARS-CoV-2 infection]

Authors:  Cristina Lavilla Olleros; Marina López-Rubio; Chiara Fanciulli; Adriana González-Munera; Jesús Millán Núñez-Cortés
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-12-28

5.  Severe Headache, Paraesthesias, Facial Diplegia and Pleocytosis: A Misleading Presentation of Guillain-Barré Syndrome.

Authors:  Mohamed Reda Belkhribchia; Abderrahim Chekabab; Yahya Naji; Latifa Hadrane; Soufiane Hassar; Nissrine Louhab; Najib Kissani
Journal:  Eur J Case Rep Intern Med       Date:  2021-01-29

6.  Guillain-Barré syndrome variant with facial diplegia and paresthesias after reactivation of varicella zoster virus.

Authors:  Xiaodong Chen; Ying Wang; Yongjun Cao
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.830

7.  The Ultimate Poker Face: A Case Report of Facial Diplegia, a Guillain-Barré Variant.

Authors:  Joshua Lowe; James Pfaff
Journal:  Clin Pract Cases Emerg Med       Date:  2020-04-23

8.  Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2.

Authors:  David Salomón Juliao Caamaño; Rubén Alonso Beato
Journal:  J Clin Neurosci       Date:  2020-05-14       Impact factor: 1.961

9.  Mitochondrial damage and "plugging" of transport selectively in myelinated, small-diameter axons are major early events in peripheral neuroinflammation.

Authors:  Marija Sajic; Keila Kazue Ida; Ryan Canning; Norman A Gregson; Michael R Duchen; Kenneth J Smith
Journal:  J Neuroinflammation       Date:  2018-02-27       Impact factor: 8.322

10.  Bilateral facial nerve palsy associated with COVID-19 and Epstein-Barr virus co-infection.

Authors:  A Cabrera Muras; M M Carmona-Abellán; A Collía Fernández; J M Uterga Valiente; L Antón Méndez; J C García-Moncó
Journal:  Eur J Neurol       Date:  2021-01       Impact factor: 6.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.